| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the Department of Neurology (Dr. Sandberg-Wollheim), University Hospital, Lund, Sweden; Serono, Inc. (Drs. Lopez-Bresnahan, Chang, and Francis, D. Frank), Rockland, MA; Serono (M. Stam-Moraga), Geneva, Switzerland; Department of Obstetrics and Gynecology (Dr. Goodwin), University of Southern California; and Department of Neurology (Dr. Giesser), University of California, Los Angeles.
* To whom correspondence should be addressed. E-mail: Magnhild.Sandberg{at}neurol.lu.se.
Abstract-- Background: Although patients with multiple sclerosis (MS) are advised to stop interferon (IFN) beta-1a therapy before becoming pregnant, some patients become pregnant while on treatment. Methods: We examined individual patient data from eight clinical trials with IFN
-1a. Results: Of 3,361 women in the studies, 69 pregnancies were reported, of which 41 were patients receiving (or who had stopped receiving within 2 weeks prior to conception) IFN-1a (in utero exposure group), 22 were patients who discontinued IFN-1a treatment more than 2 weeks before conception (previous exposure group), and six were patients receiving placebo. The 41 in utero exposure pregnancies resulted in 20 healthy full-term infants, one healthy premature infant, nine induced abortions, eight spontaneous abortions, one fetal death, and one congenital anomaly (hydrocephalus). One patient was lost to follow-up. The 22 previous exposure pregnancies resulted in 20 full-term healthy infants, one healthy premature infant, and one birth-related congenital anomaly (Erb palsy) Conclusions: The majority (21/31) of pregnancies that had the potential to go to full term produced healthy infants. The rate of spontaneous abortion was higher, but not significantly so, in the in utero exposure group compared to general population estimates. Until more exposure data become available, patients remain advised to stop IFN therapy before becoming pregnant.
This article has been cited by other articles:
|
|
 |
|
  C Weber-Schoendorfer and C Schaefer Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study Multiple Sclerosis, September 1, 2009; 15(9): 1037 - 1042. [Abstract] [PDF]
|
|
|
|
|
|
N Fernandez Liguori, D Klajn, L Acion, F Caceres, A Calle, A Carra, E Cristiano, N Deri, O Garcea, A Jaureguiberry, et al. Epidemiological characteristics of pregnancy, delivery, and birth outcome in women with multiple sclerosis in Argentina (EMEMAR study) Multiple Sclerosis, May 1, 2009; 15(5): 555 - 562. [Abstract] [PDF]
|
|
|
|
|
|
Y. Chen, H. Lin, and H. Lin Does multiple sclerosis increase risk of adverse pregnancy outcomes? A population-based study Multiple Sclerosis, May 1, 2009; 15(5): 606 - 612. [Abstract] [PDF]
|
|
|
|
 |
|
 M Lee and P O'Brien Pregnancy and multiple sclerosis J. Neurol. Neurosurg. Psychiatry, December 1, 2008; 79(12): 1308 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Argyriou and N. Makris Review Article: Multiple Sclerosis and Reproductive Risks in Women Reproductive Sciences, October 1, 2008; 15(8): 755 - 764. [Abstract] [PDF]
|
|
|
|
 |
|
 Does Interferon Beta Affect Pregnancy? Journal Watch Neurology, November 28, 2005; 2005(1128): 1 - 1. [Full Text]
|
|
|
|
 |
|
 E. Waubant and A. D. Sadovnick Interferon beta babies Neurology, September 27, 2005; 65(6): 788 - 789. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
